Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, Hayashi H, Sakai K, Chiba Y, Tsuya A, Goto H, Otsuka E, Okida H, Kobayashi M, Yoshimoto R, Funabashi M, Hashimoto Y, Hirotani K, Kagari T, Nishio K, Nakagawa K. Yonesaka K, et al. Among authors: hashimoto y. Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17. Clin Cancer Res. 2022. PMID: 34921025
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, Abe M, Kaneda Y, Maeda N, Shiose Y, Iguchi T, Ishizaka T, Karibe T, Hayakawa I, Morita K, Nakada T, Nomura T, Wakita K, Kagari T, Abe Y, Murakami M, Ueno S, Agatsuma T. Hashimoto Y, et al. Clin Cancer Res. 2019 Dec 1;25(23):7151-7161. doi: 10.1158/1078-0432.CCR-19-1745. Epub 2019 Aug 30. Clin Cancer Res. 2019. PMID: 31471314
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.
Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Ott M, et al. Among authors: hashimoto y. Clin Cancer Res. 2020 Sep 15;26(18):4983-4994. doi: 10.1158/1078-0432.CCR-19-4092. Epub 2020 Jun 30. Clin Cancer Res. 2020. PMID: 32605912 Free PMC article.
Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Qin Y, et al. Among authors: hashimoto y. Mol Cancer Ther. 2016 Oct;15(10):2442-2454. doi: 10.1158/1535-7163.MCT-15-0963. Epub 2016 Jul 25. Mol Cancer Ther. 2016. PMID: 27458138 Free PMC article.
Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM. Everson RG, et al. Among authors: hashimoto y. J Neurooncol. 2018 Sep;139(2):469-478. doi: 10.1007/s11060-018-2891-8. Epub 2018 May 30. J Neurooncol. 2018. PMID: 29846894
Rethinking medulloblastoma from a targeted therapeutics perspective.
Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Hashimoto Y, et al. J Neurooncol. 2018 Sep;139(3):713-720. doi: 10.1007/s11060-018-2917-2. Epub 2018 Jun 5. J Neurooncol. 2018. PMID: 29869738 Free PMC article.
Upstroke time is a more useful marker of atherosclerosis than percentage of mean arterial pressure for detecting coronary artery disease in subjects with a normal ankle-brachial index.
Maruhashi T, Kajikawa M, Kishimoto S, Yamaji T, Harada T, Hashimoto Y, Mizobuchi A, Tanigawa S, Yusoff FM, Nakano Y, Chayama K, Nakashima A, Goto C, Higashi Y. Maruhashi T, et al. Among authors: hashimoto y. Hypertens Res. 2024 May 17. doi: 10.1038/s41440-024-01707-6. Online ahead of print. Hypertens Res. 2024. PMID: 38760524
Real-World Patent Foramen Ovale (PFO) Closure in Japan　- 30-Day Clinical Outcomes From the AmplatzerTM PFO Occluder Japan Post-Marketing Surveillance Study.
Akagi T, Hara H, Kanazawa H, Fukui S, Hashimoto Y, Iguchi Y, Iwama T, Kataoka H, Kawamura A, Kawano H, Oki K, Yamagami H; PFO Japan PMS Investigators. Akagi T, et al. Among authors: hashimoto y. Circ J. 2024 May 11. doi: 10.1253/circj.CJ-24-0080. Online ahead of print. Circ J. 2024. PMID: 38735702 Free article.
5,232 results